Weight-loss projection calculator
See an estimated week-by-week curve based on clinical-trial averages. Adjust your starting weight, drug, and timeframe.
This tool estimates total body-weight loss over time using the average results from each drug's pivotal clinical trial. Real results vary widely from person to person and depend on dose, diet, activity, and how long you stay on treatment. Use this as a rough planning guide, not a promise.
Model uses an ease-out curve approaching each drug's trial-average loss at its study endpoint.
Projected curve
Week-by-week estimate
| Week | Projected weight | Total lost | % of body weight |
|---|
About these numbers
The percentages reflect average total body-weight reductions reported in the medications' pivotal trials: roughly 15% for semaglutide 2.4 mg (Wegovy) at 68 weeks and roughly 20% for tirzepatide (Zepbound) at 72 weeks. Weight loss generally builds gradually during dose titration and then continues more slowly. Stopping treatment often leads to partial regain.
Your results depend on many personal factors. Discuss realistic goals with your prescriber.
Sources: FDA.gov drug labeling for Wegovy and Zepbound; published pivotal trial summaries.